References
Leroy EM, Gonzalez J-P, Baize S (2011) Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect 17:964–976. doi:10.1111/j.1469-0691.2011.03535.x
Feldmann H, Geisbert TW (2011) Ebola haemorrhagic fever. Lancet 377:849–862. doi:10.1016/S0140-6736(10)60667-8
WHO Ebola Response Team (2014) Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. N Engl J Med. 371:1481–1495. doi:10.1056/NEJMoa1411100
Cohen J (2002) The immunopathogenesis of sepsis. Nature 420:885–891
Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369:840–851. doi:10.1056/NEJMra1208623
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Intensive Care Med 39(2):165–228. doi:10.1007/s00134-012-2769-8
McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, Spiropolou CF (2014) Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis 210(4):558–566. doi:10.1093/infdis/jiu088
Bente D, Gren J, Strong JE, Feldmann H (2009) Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2:12–17. doi:10.1242/dmm.000471
Geisbert TW, Jahrling PB (2004) Exotic emerging viral diseases: progress and challenges. Nature Med 10(Suppl 12):S110–121. doi:10.1038/nm1142
Mahanty S, Bray M (2004) Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4(8):487–498
Mohamadzadeh M, Chen L, Schmaljohn AL (2007) How Ebola and Marburg viruses battle the immune system. Nat Rev Immunol 7:556–567. doi:10.1038/nri2098
Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, Hensley LE (2003) Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163:2371–2382
Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB, Zaki SR, Swanepoel R, Ansari AA, Peters CJ (1999) Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 179(Suppl 1):S188–191. doi:10.1086/514283
Hensley LE, Young HA, Jahrling PB, Geisbert TW (2002) Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 80:169–179. doi:10.1016/s0165-2478(01)00327-3
Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW (2004) Depletion of peripheral blood T lymphocytes and NK cells during the course of ebolahemorrhagic fever in cynomolgus macaques. Viral Immunol 17:390–400. doi:10.1089/vim.2004.17.390
Leblebicioglu H, Bodur H, Dokuzoguz B, Elaldi N, Guner R, Koksal I, Kurt H, Senturk GC (2012) Case management and supportive treatment for patients with Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 12:805–811. doi:10.1089/vbz.2011.0896
Rollin PE, Bausch DG, Sanchez A (2007) Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola Virus. J Infect Dis 196(Suppl 2):S364–371
Mupere E, Kaducu OF, Yoti Z (2001) Ebola haemorrhagic fever among hospitalised children and adolescents in nothern Uganda : epidemiologic and clinical observations. Afr Hlth Sci 1(2): 60–65. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2141551/
Goodman JL (2014) Studying “Secret Serums”—toward safe, effective Ebola treatments. N Engl J Med 371:108–1089. doi:10.1056/NEJMp1409817
Fowler RA, Fletcher T, Fischer WA, Lamontagne F, Jacob S, Brett-Major D et al (2014) Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med 190(7):733–737
Acknowledgments
Drs Fletcher and Fowler both provide assistance to Ebola Treatment Centres in West Africa, supported by the World Health Organization. Dr Fletcher receives support from the Wellcome Trust and from the Ministry of Defence. Dr Fowler is a clinician scientist of the Heart and Stroke Foundation (Ontario, Canada). Dr Beeching is partially supported by a National Institute of Health Research grant to the Health Protection Research Unit in Emerging and Zoonotic Infections, a collaboration between the University of Liverpool, Liverpool School of Tropical Medicine and Public Health England. Views expressed are those of the authors.
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fletcher, T.E., Fowler, R.A. & Beeching, N.J. Understanding organ dysfunction in Ebola virus disease. Intensive Care Med 40, 1936–1939 (2014). https://doi.org/10.1007/s00134-014-3515-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-014-3515-1